.jpeg)
2026-10-14 04:43:35
Stiripentol is an oral antiseizure drug for Dravet-syndrome–related seizures in patients aged 6 months or older, weighing at least 7kg, and already receiving clobazam. It is not monotherapy. Use 50mg/kg/day in 2–3 divided doses, max 3000mg/day, with meals; monitor somnolence, appetite/weight loss, ataxia, neutropenia, thrombocytopenia, and clobazam interactions.
2026-10-14 04:40:08
This article reviews the mechanism, indications, dosing, toxicity management, and global clinical data of Selinexor, providing an objective reference for RRMM patients.
2026-10-13 07:01:50
Acalabrutinib is a selective BTK inhibitor that covalently blocks the BTK active-site cysteine and interrupts BCR downstream signaling in CLL/SLL and related B-cell tumors. It affects malignant and normal B cells, so infection, bleeding, arrhythmia, cytopenias, and resistance pathways all require structured monitoring.
2026-10-13 06:58:10
Bosutinib is an oral BCR-ABL and SRC-family tyrosine kinase inhibitor for newly diagnosed or resistant/intolerant Philadelphia chromosome-positive chronic-phase CML in adults, resistant/intolerant accelerated or blast-phase CML in adults, and chronic-phase CML in children aged 1 year and older. Main safety work covers diarrhea, liver injury, myelosuppression, and fluid retention.
2026-10-13 06:54:53
FDA approved Hovilpri (pritelivir) 100mg tablets for immunocompromised adults with HSV mucocutaneous disease refractory to acyclovir, valacyclovir, or famciclovir. It inhibits the HSV helicase-primase complex and may work against some nucleoside-resistant strains; PRIOH-1 showed 63% vs 34% complete healing at 28 days. Assess immune status, renal function, drug interactions, and headache.
2026-10-12 06:45:08
Venetoclax is a selective BCL-2 inhibitor for adult CLL/SLL and for AML unfit for intensive chemotherapy in combination regimens. A 5-week CLL ramp to 400mg daily and a 3–4-day AML ramp reduce tumor lysis risk; myelosuppression, infections, and CYP3A interactions require structured monitoring. Some overseas markets add fixed-duration BCL-2 plus BTK first-line CLL pathways.
2026-10-12 06:15:41
Zongertinib is an oral highly selective HER2 tyrosine kinase inhibitor for unresectable locally advanced or metastatic non-small-cell lung cancer with confirmed HER2/ERBB2 tyrosine kinase domain activating mutations. In Beamion LUNG-1, first-line ORR was about 76% and median PFS 14.4 months; active brain metastases had intracranial ORR about 47%. Previously treated cohorts showed ORR about 71% and median PFS 12.4 months. Main issues are diarrhea, rash, transaminase elevation, and vigilance for ILD and LVEF decline.
2026-10-10 07:13:01
In July 2026, FDA converted selpercatinib (Retevmo) for RET fusion locally advanced or metastatic solid tumors from accelerated to traditional approval, covering ages 2 and older. In LIBRETTO-001 non-lung/non-thyroid cohort ORR was 47% and median DOR 24.5 months; adults 12+ use 120 or 160mg twice daily by weight, younger children use BSA-based dosing, with ongoing monitoring of transaminases, blood pressure, QTc, thyroid, and pediatric growth plates.
2026-10-10 07:07:16
On October 8, 2026, FDA approved atezolizumab, including Tecentriq Hybreza subcutaneous formulation, with fluoropyrimidine and oxaliplatin for adjuvant treatment of resected stage III dMMR colon cancer. In ATOMIC, adding atezolizumab to mFOLFOX6 halved relapse/death risk versus chemotherapy alone. Monitor immune pneumonitis, hepatitis, colitis, endocrinopathies, and oxaliplatin neuropathy.
2026-10-09 06:37:20
In October 2026, FDA expanded pirtobrutinib (Jaypirca) for previously untreated adults with CLL/SLL and no known 17p deletion. In BRUIN CLL-313, 200mg once daily versus bendamustine plus rituximab gave median PFS not reached vs 33.5 months; manage infection, bleeding, cytopenias, arrhythmia, hepatotoxicity, and second cancers.
2026-10-09 05:43:21
On October 7, 2026, FDA approved tucatinib (Tukysa) 300mg twice daily with trastuzumab and pertuzumab for maintenance in adults with unresectable locally advanced or metastatic HER2-positive breast cancer who did not progress after THP induction. In HER2CLIMB-05, median PFS was 24.9 vs 16.3 months; monitor hepatotoxicity, diarrhea, serum creatinine, and embryo-fetal risk.
2026-10-08 07:27:42
Acoramidis is an oral TTR stabilizer for adults with wild-type or variant transthyretin amyloid cardiomyopathy. It binds TTR thyroxine-binding sites and mimics T119M stabilization to reduce tetramer dissociation and amyloid deposition. In ATTRibute-CM, 712mg twice daily lowered CV death/hospitalization and blunted NT-proBNP rise; monitor diarrhea, abdominal pain, creatinine/eGFR, and TSH.
